

Summary

XSONX is dedicated to improving wound hygiene, which is critical to help eradicate bacterial biofilms and improve healing. We have a two-step approach.

Step one is to use XSONX Wound Hygiene System to clean and debride wounds better and with less pain. XSONX is innovative and cost-effective.

Step two is to use XSONX Wound Dressings with ISORBX™ between treatments to finish off the biofilm and protect the wound as it heals.

Together, XSONX solutions will help improve wound hygiene and patient care.

Together, the XSONX one-two punch will improve eradication of biofilms, speed wound healing, and reduce complications with less pain than standard treatments.

The Problem

Complications from chronic nonhealing wounds result in significant morbidity and mortality.

Up to **90%** of chronic wounds and **7%** of acute wounds have bacterial biofilms, which cause inflammation & increase infection risk. Bacteria in biofilms are up to **1000x** resistant to antibiotics and can regrow within 24-72 hours after debridement. Current practice includes serial sharp debridement of wounds, but pain affects compliance. Common wound cleansing methods work poorly to prevent biofilm, and nothing to treat biofilm.

Our Two-Step Solution

XSONX Wound Hygiene System

Micro-vibrations powerfully clean and debride wounds. We intend to prove that XSONX improves removal of biofilm better, smoother, and with less pain. Engineered to be easy to use and cost-effective, using existing reimbursement codes. Use to clean and debride wounds.

XSONX Wound Dressings with ISORBX™

XSONX wound dressings can absorb significant wound drainage, and in turn release small amounts of iodine into the wound slowly over time. We have engineered a full range of proprietary dressings, useful for all stages of wound healing.

Market Size

- 300 MM-650 MM wound dressings done annually in the U.S. alone.
- 4.5 MM wound debridement procedures done annually in the U.S.
- 8.2 MM people effected by chronic wounds in the U.S. alone
- \$28 B - \$96 B annual cost of treating wounds in the U.S..

The most common methods of cleaning wounds works poorly to prevent biofilm and does nothing to treat biofilm

How We Will Drive Adoption

XSONX plans on controlling our own destiny and commercializing our products ourselves. We will outsource where possible and focus on strong internal core competencies in digital marketing, direct sales, product development, and customer service. We will use a hands-on educational focus heavy on virtual and in-person demonstrations to drive sales.

Leadership

XSONX was founded by an engineer, Wound Care Specialist Physician, and medical device executive with unique full cycle med-tech success, who has proven success previously running a large wound care division. XSONX leadership includes decades of experience in device regulatory, design, engineering, & medical device marketing.

Current Status

XSONX Wound Hygiene System is fully developed and ready for design freeze. XSONX Wound Dressings with ISORBX technology is licensed to XSONX exclusively world wide, with a full product range of wound dressings already developed. XSONX and each dressing will require separate regulatory approval. XSONX will use funding for basic clinicals and achieving FDA clearances on initial product lines.

\$600k+

Self funding to date.

>70%

Gross Margins with our cost-effective XSONX solutions.

\$1.5M

Funding sought to get 3 products FDA approved. 2nd \$1.5M round planned for commercialization phase.